Skip to main content
Springer Nature Link
Log in

The Humanistic, Societal, and Pharmaco-economic Burden of Angioedema

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a rare disorder characterized by intermittent and unpredictable episodes of swelling which cause disfigurement, disability, pain, or, in case of laryngeal swelling, risk of death. Historical factors, including the intermittent nature of the disorder, the lack of awareness of this ultra-rare condition amongst medical personnel, lack of specialist centers, and limited treatment options have contributed to under-diagnosis and under-treatment of the condition. Incorrect treatment of attacks has been common, even when medical help is sought. This has lead to reduced health-seeking behavior and alternative coping strategies, sometimes even denial, in many families, while a minority of HAE-affected patients have become serial emergency room attenders with chronic pain and ongoing requirement for opiate-based painkillers. Both strategies have incurred not only physical but also psychological and economic consequences.

In the last 10 years, new and effective acute therapies have been made available, some of which have also provided short-term and long-term prophylaxis options, together with a better understanding of older prophylactic drugs. Improved awareness of HAE amongst the general public, family members, and physicians has reduced the long delay in diagnosis and increased the number of patients receiving effective and up-to-date therapies to improve the physical impact of the disorder.

Data on the impact of treatment on the psychological outcomes is scarce, but the limited information available suggests that access to specialist advice and treatment leads to psychological as well as physical improvement.

HAE also has profound effects on individual and family economic output, directly via absenteeism from school or work and indirectly via lost opportunities. Economic improvements associated with better treatments are offset by the high cost of new acute treatments, resulting in difficult pharmaco-economic calculations. Worldwide, cost considerations present potentially insurmountable barriers to treatment for many patients, depending on the healthcare system in the individual country.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT (2010) The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 31(5):407–414

    Article  PubMed  Google Scholar 

  2. Caballero T, Caminoa M, Prior N, Gómez-Traseira C, Pérez E, Forjaz MJ, the DV-IHAE QoL group (2011) Health-related quality of life in adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) as measured by SF-36v2: preliminary results of an international study. J Angioedema 1:14–15 [Abstract]

    Google Scholar 

  3. Gomide MACMS, Toledo E, Rodrigues Valle SO, Campos RA, Franca AT, Gomez NP, Andrade HF Jr, Caballero T, Grumach AS (2013) Hereditary angioedema: quality of life in Brazilian patients. Clinics (Sao Paolo) 68(1):81–83

    Article  Google Scholar 

  4. Jolles S, Williams P, Carne E, Mian H, Huissoon A, Wong G, Hackett S, Lortan J, Platts V, Longhurst H, Grigoriadou S, Dempster J, Deacock S, Khan S, Darroch J, Simon C, Thomas M, Pavaladurai V, Alachkar H, Herwadkar A, Abinun M, Arkwright P, Tarzi M, Helbert M, Bangs C, Pastacaldi C, Phillips C, Bennett H, El-Shanawany T (2014) A Uk national audit of hereditary and acquired angioedema. Clin Exp Immunol 175(1):59–67

    Article  CAS  PubMed  Google Scholar 

  5. Bygum A (2014) Hereditary angioedema—consequences of a new treatment paradigm in Denmark. Acta Derm Venereol 94:436–441

    Article  CAS  PubMed  Google Scholar 

  6. Bouillet L, Launay D, Fain O, Boccon-Gibod I, Laurent J, Martin L, Monauban V, Finck K, Bouée S, Gompel A, Kanny G, French National Reference Center for Hereditary Angioedema (CREAK) (2013) Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. Ann Allergy Asthma Immunol 111:290–294

    Article  CAS  PubMed  Google Scholar 

  7. Christiansen SC, Bygum A, Banerji A, Busse P, Li H, Lumry W, Davis-Lorton M, Bernstein JA, Frank MM, Castaldo A, Long JF, Riedl M, Zuraw BL (2015) Before and after, the impact of available on-demand treatment for HAE. Allergy Asthma Proc 36:145–150

    Article  PubMed  Google Scholar 

  8. Fouche AS, Saunders EF, Craig T (2014) Depression and anxiety in patients with hereditary angioedema. Ann Allergy Asthma Immunol 112(4):371–375

    Article  CAS  PubMed  Google Scholar 

  9. Bygum A, Aygören-Pürsün E, Caballero T, Beusterien K, Gholizadeh S, Musingarimi P, Wait S, Boysen H (2012) The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology. Dermatology 12(4):1–9

    Google Scholar 

  10. Caballero T, Aygören-Pürsün E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, Wait S, Boysen HB (2014) The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. Allergy Asthma Proc 35(1):47–53

    Article  PubMed  Google Scholar 

  11. Bygum A, Andersen KE, Mikkelsen CS (2009) Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 19(2):147–151

    PubMed  Google Scholar 

  12. Bork K, Witzke G (1989) Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immuno 83(3):677–682

    Article  CAS  Google Scholar 

  13. Aygören-Pürsün E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W (2010) On demand treatment and home therapy of hereditary angioedema in Germany—the Frankfurt experience. Allergy, Ast & Clin Immunol 6:21

    Article  Google Scholar 

  14. Nordenfelt P, Dawson S, Wahlgren CF, Lindfors A, Mallbris L, Bjorkander J (2014) Quantifying the burden of disease and perceived health state in patients with hereditary angioedema in Sweden. Allergy Asthma Proc 35(2):185–190

    Article  PubMed  Google Scholar 

  15. Freitag FG (2007) The cycle of migraine: patients’ quality of life during and between migraine attacks. Clin Ther 29:939

    Article  PubMed  Google Scholar 

  16. Bygum A, Aygören-Pürsün E, Beusterien K, Hautamaki E, Sisic Z, Wait S, Boysen HB, Caballero T (2015) Burden of illness in hereditary angioedema: a conceptual model. Acta Derm Venereol 95:706–710

    Article  PubMed  Google Scholar 

  17. Dantzer R (2012) Depression and inflammation: an intricate relationship. Biol Psychiatry 71:4–5

    Article  PubMed  Google Scholar 

  18. Banerji A, Busse P, Christiansen SC, Li H, Lumry W, Davis-Lorton M, Bernstein JA, Frank M, Castaldo A, Long JF, Zuraw BF, Riedl M (2015) Current state of hereditary angioedema management: a patient survey. Allergy Asthma Proc 36:213–217

    Article  PubMed  PubMed Central  Google Scholar 

  19. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE (2010) Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 104:314–320

    Article  PubMed  Google Scholar 

  20. Aygören-Pürsün E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, Wait S, Boysen HB, Caballero T (2014) Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. Orphanet J Rare Diseases 9:99

    Article  Google Scholar 

  21. Ohsawa I, Honda D, Nagamachi S, Hisada A, Shimamoto M, Inoshita H, Mano S, Tomino Y (2015) Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in Japan. Ann Allergy Asthma Immunol 114(6):492–498. doi:10.1016/j.anai.2015.03.010, Epub 2015 Apr 11

    Article  PubMed  Google Scholar 

  22. NHS Commissioning Board Clinical Commissioning Policy: Treatment of Acute Attacks in Hereditary Angioedema. https://www.england.nhs.uk/wp-content/uploads/2013/04/b09-p-b.pdf, accessed 13 Jan 2016

  23. Read N, Lim E, Tarzi MD, Hildick-Smith P, Burns S, Fidler KJ (2014) Paediatric hereditary angioedema: a survey of UK service provision and patient experience. Clinical Exp Immunol 178:483–488

    Article  CAS  Google Scholar 

  24. Tilles SA, Borisch L, Cohen JP (2013) Management of hereditary angioedema in 2012: scientific and pharmacoeconomic perspectives. Ann Allergy Asthma Immunol 110:70–74

    Article  PubMed  Google Scholar 

  25. Speciality Pharmacy News (2012) 9(7), 9–11

  26. Helbert M, Holbrook T, Drogon E, Mannan A (2013) Exploring cost and burden of illness of HAE in the UK. Poster UKPIN, Liverpool

    Google Scholar 

  27. Cardarelli W (2013) Managed care implications of hereditary angioedema. Am J Managed Care 19:S119–S124

    Google Scholar 

  28. http://formularyjournal.modernmedicine.com/formulary-journal/news/study-drug-costs-hereditary-angioedema-tripled-2-years?page=0,0. Accessed 28 Jan 2016

  29. Kawalec P, Holko P, Paszulewicz A (2013) Cost-utility analysis of Ruconest (conestat alfa) compared to Berinert P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema. Postep Derm Alergol 3:152–158

    Article  Google Scholar 

  30. Manson AL, Price A, Dempster J, Clinton-Tarestad P, Greening C, Enti R, Hill S, Grigoriadou S, Buckland MS, Longhurst HJ (2013) In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency. Clin Exp Immunol 173:1–7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Bork K (2016) A decade of change: recent developments in pharmacotherapy of Hereditary Angioedema (HAE) Clin Rev Allergy Immunol (this issue)

  32. Jose J, Zacharias J, Craig T (2016) Review of Select Practice parameters, Evidence-Based Treatment Algorithms, and International Guidelines for Hereditary Angioedema. Clin Rev Allergy Immunol (this issue)

  33. Lumry WR, Miller DP, Newcomer S et al (2014) Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy Asthma Proc 35(5):371–376

    Article  CAS  PubMed  Google Scholar 

  34. Reshef A, Kidon M, Leibovich I (2016) The Story of Angioedema: from Quincke to Bradykinin. Clin Rev Allergy Immunol. doi:10.1007/s12016-016-8553-8

  35. Hack CE, Relan A, Van Amersfoort ES et al (2012) Target levels of functional C1-inhibitor in hereditary angioedema. Allergy 67(1):123–130

    Article  CAS  PubMed  Google Scholar 

  36. Bork K, Hardt J, Witzke G (2012) Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 130(3):692–697

    Article  PubMed  Google Scholar 

  37. Zanichelli A, Magerl M, Longhurst H et al (2013) Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy, Asthma Clin Immunol 9(1):29, http://www.aacijournal.com/content/9/1/29

    Article  Google Scholar 

  38. Frank MM, Gelfand JA, Atkinson JP (1976) Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 84:580–593

    Article  CAS  PubMed  Google Scholar 

  39. Agostoni A, Cicardi M (1992) Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine 71:206–215

    Article  CAS  PubMed  Google Scholar 

  40. Bygum A (2009) Hereditary angio-oedema (HAE) in Denmark: a nationwide survey. Br J Dermatol 161:1153–1158

    Article  CAS  PubMed  Google Scholar 

  41. Psarros F, Koutsostathis N, Farmaki E, Speletas MG, Germenis AE (2014) Hereditary angioedema in Greece: the first results of the Greek hereditary angioedema registry. Int Arch Allergy Immunol 164(4):326–332

    Article  PubMed  Google Scholar 

  42. Speletas M, Szilagyi A, Psarros F, Moldovan D, Magerl M, Kompoti M, Gramoustianou E, Bors A, Mihaly E, Tordai A, Avramouli A, Varga L, Maurer M, Farkas H, Germenis AE (2015) J Allergy Clin Immunol 135:570–573

    Article  PubMed  Google Scholar 

  43. Zuraw BL, Banerji A, Bernstein JA, Busse PJ, Christiansen SC, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Riedl M (2013) Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract 1(5):458–467. doi:10.1016/j.jaip.2013.07.002

    Article  PubMed  Google Scholar 

  44. Nasr IH, Manson AL, Al Wahshi HA, Longhurst HJ (2015) Optimizing hereditary angioedema management through tailored treatment approaches. Expert Rev of Clin Immunol, DOI: 10.1586/1744666X. 2016.1100963

  45. Aygören-Pürsün E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W (2010) On demand treatment and home therapy of hereditary angioedema in Germany—the Frankfurt experience. Allergy, Asthma Clin Immunol 6(1):21. doi:10.1186/1710-1492-6-21, 6: 21–24

    Article  Google Scholar 

  46. Levi M, Choi G, Picavet C, Hack CE (2006) Self administration of C1 inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 117:904–908

    Article  CAS  PubMed  Google Scholar 

  47. Longhurst HJ, Farkas H, Craig T et al (2010) HAE international home therapy consensus document. Allergy, Asthma Clin Immunol 6(1):22, http://www.aacijournal.com/content/6/1/22

    Article  Google Scholar 

  48. Kreutz W, Martinez-Saguer I, Aygoren-Pursun E, Rusicke E, Heller C, Klingebiel T (2009) C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 49:1987–1995

    Article  Google Scholar 

  49. Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A, Caballero T, Bloom B, Nair N, Malbran A (2014) Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy 69:305–314

    Article  CAS  PubMed  Google Scholar 

  50. Maurer M, Longhurst HJ, Fabien V, Li HH, Lumry W, for the IOS Study Group (2014) Treatment of hereditary angioedema with icatibant: Efficacy in clinical trials versus effectiveness in the real-world setting. Allergy Asthma Proc 35:1–5

    Article  Google Scholar 

  51. HernándezFernandezdeRojas D, Ibañez E, Longhurst H, Maurer M, Fabien V, Aberer W, Bouillet L, Zanichelli A, Caballero T, IOS Study Group (2015) Treatment of HAE attacks in the icatibant outcome survey: an analysis of icatibant self-administration versus administration by health care professionals. Int Arch Allergy Immunol 167(1):21–28

    Article  Google Scholar 

  52. Tachdjian R, Banerji A, Guyer A, Morphew T (2015) Current characteristics associated with hereditary angioedema attacks and treatment: the home infusion-based patient experience. Allergy Asthma Proc 36:151–159

    Article  PubMed  Google Scholar 

  53. Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M (2011) Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 66:192–196

    Article  CAS  PubMed  Google Scholar 

  54. Lane CJ, Grant JA, Dougherty D (2012) Life with hereditary angioedema: then and now postgraduate. Medicine 124(1):144–151

    Google Scholar 

  55. Blasco A, Lázaro P, Caballero T, Guilarte M (2013) Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain. Heal Econ Rev 3:2

    Article  Google Scholar 

  56. Zilberberg M, Jacobsen T, Tillotson G (2010) The burden of hospitalisations and emergency department visits with hereditary angioedema and angioedema in the United States 2007. Allergy Asthma Proc 31:511–519

    Article  PubMed  Google Scholar 

  57. http://haei.org/hae/global_access_program/. Accessed 26 Jan 2016

  58. Malbrán A, Malbrán E, Menendez A, Fernandez Romero DS (2014) Angioedema Hereditario. Tratamiento del Ataque Agudo en la Argentina. Medicina (Buenos Aires) 74:198–200 [Spanish]

    Google Scholar 

  59. Longhurst HJ, Tarzi MD, Ashworth F, Bethune C, Cale C, Dempster J, Gompels M, Jolles S, Seneviratne S, Symons C, Price A, Edgar D (2015) C1 inhibitor deficiency: 2014 United Kingdom consensus document. Clin Exp Immunol 180(3):475–483

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Weller K, Groffik A, Margerl M, Tohme N, Martus P, Krause K, Metz M, Staubach P, Maurer M (2013) Development, validation, and initial results of the Angioedema Activity Score. Allergy 68(9):1185–1192

    CAS  PubMed  Google Scholar 

  61. Prior N, Remor E, Gómez-Traseira C, López-Serrano C, Cabañas R, Contreras J, Campos Á, Cardona V, Cimbollek S, González-Quevedo T, Guilarte M, de Rojas DH, Marcos C, Rubio M, Tejedor-Alonso MÁ, Caballero T (2012) Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project. Health Qual Life Outcomes 10:82. doi:10.1186/1477-7525-10-82

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Barts Health NHS Trust London, London, E1 2ES, UK

    Hilary Longhurst

  2. HAE Centre Denmark, Department of Dermatology and Allergy Centre, Odense University Hospital, 5000, Odense C, Denmark

    Anette Bygum

Authors
  1. Hilary Longhurst
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Anette Bygum
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Hilary Longhurst.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Longhurst, H., Bygum, A. The Humanistic, Societal, and Pharmaco-economic Burden of Angioedema. Clinic Rev Allerg Immunol 51, 230–239 (2016). https://doi.org/10.1007/s12016-016-8575-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-016-8575-2

Keywords